m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02633)
Name
Pirarubicin
Synonyms
pirarubicin; Theprubicin; MFCD00869742; THP-doxorubicin; C32H37NO12; NCGC00167982-01; AC1LCS5T; Pirarubicin (JP17/INN); SCHEMBL15472856; CHEMBL1398373; EX-A494; AOB5649; KMSKQZKKOZQFFG-HSUXVGOQSA-N; ZINC3913909; AKOS015895621; NCGC00167982-02; BC225325; K234; D01885; 15207-EP2316833A1; 15207-EP2311829A1; 15207-EP2298765A1; 15207-EP2298748A2; 15207-EP2295427A1; 15207-EP2295416A2; 15207-EP2272827A1; 15207-EP2316832A1; 15207-EP2298778A1; 15207-EP2298768A1; 15207-EP2295426A1; 15207-EP2295055A2; 15207-EP2311808A1
    Click to Show/Hide
Status
Approved
Structure
Formula
C32H37NO12
InChI
1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21-,22-,31+,32-/m0/s1
InChIKey
KMSKQZKKOZQFFG-HSUXVGOQSA-N
PubChem CID
636397
VARIDT Drug ID
DR01430
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Pirarubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pirarubicin through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Pirarubicin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pirarubicin through regulating the expression of P-glycoprotein 1 (ABCB1). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Pirarubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pirarubicin through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [4]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10. doi: 10.1007/s00280-008-0838-z. Epub 2008 Sep 27.
Ref 3 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 4 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.